CY1122724T1 - Ρυθμιση της δραστικοτητας των προνευροτροφινων - Google Patents

Ρυθμιση της δραστικοτητας των προνευροτροφινων

Info

Publication number
CY1122724T1
CY1122724T1 CY20201100206T CY201100206T CY1122724T1 CY 1122724 T1 CY1122724 T1 CY 1122724T1 CY 20201100206 T CY20201100206 T CY 20201100206T CY 201100206 T CY201100206 T CY 201100206T CY 1122724 T1 CY1122724 T1 CY 1122724T1
Authority
CY
Cyprus
Prior art keywords
pro
disorders
binding
proneurotrophins
regulation
Prior art date
Application number
CY20201100206T
Other languages
English (en)
Inventor
Anders Nykjaer
Olav Michael Andersen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1122724T1 publication Critical patent/CY1122724T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει παράγοντες για την αναστολή της δεσμεύσεως μίας προ-νευροτροφίνης σε έναν υποδοχέα πεδίου Vps10p συγκεκριμένα της δεσμεύσεως ενός προ-ΝGF ή ενός προ-ΒDNF σε έναν υποδοχέα σορτιλίνης. Η εφεύρεση κατά συνέπεια παρέχει παράγοντες για την κατασκευή ενός φαρμάκου, για την αγωγή και/ή την πρόληψη νόσου ή διαταραχών όπως, αλλά όχι περιοριστικά, νευρολογικών, νευροψυχιατρικών και οφθαλμικών νόσων, διαταραχών και εκφυλίσεως καθώς επίσης και της παχυσαρκίας, του διαβήτη, του άλγους και/ή της αλγαισθησίας σε ένα άτομο.
CY20201100206T 2006-12-21 2020-03-09 Ρυθμιση της δραστικοτητας των προνευροτροφινων CY1122724T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200601692 2006-12-21
US88077107P 2007-01-16 2007-01-16
EP07846437.7A EP2120997B1 (en) 2006-12-21 2007-12-21 Modulation of activity of proneurotrophins
PCT/DK2007/000567 WO2008074329A2 (en) 2006-12-21 2007-12-21 Modulation of activity of proneurotrophins

Publications (1)

Publication Number Publication Date
CY1122724T1 true CY1122724T1 (el) 2021-03-12

Family

ID=39536772

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100465T CY1118902T1 (el) 2006-12-21 2017-04-25 Ρυθμιση της δραστικοτητας των προνευροτροφινων
CY20201100206T CY1122724T1 (el) 2006-12-21 2020-03-09 Ρυθμιση της δραστικοτητας των προνευροτροφινων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100465T CY1118902T1 (el) 2006-12-21 2017-04-25 Ρυθμιση της δραστικοτητας των προνευροτροφινων

Country Status (14)

Country Link
US (3) US8748384B2 (el)
EP (2) EP2120997B1 (el)
CY (2) CY1118902T1 (el)
DK (2) DK3225251T3 (el)
ES (2) ES2624180T3 (el)
HK (1) HK1245088A1 (el)
HR (2) HRP20170530T1 (el)
HU (2) HUE031611T2 (el)
LT (2) LT3225251T (el)
PL (2) PL2120997T3 (el)
PT (2) PT3225251T (el)
RS (2) RS60019B1 (el)
SI (2) SI2120997T1 (el)
WO (1) WO2008074329A2 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60019B1 (sr) * 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
KR101614558B1 (ko) 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
US9084745B2 (en) 2008-05-22 2015-07-21 H. Lundback A/S Modulation of the Vps10p-domain for the treatment of cardiovascular disease
DK2732823T3 (da) * 2008-06-25 2019-09-16 H Lundbeck As Modulering af TrpV : Vps10p-domæne-receptorsystemet til behandlingen af smerte
CN102439041B (zh) 2008-12-19 2016-05-04 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
WO2013156031A2 (en) * 2012-04-17 2013-10-24 Aarhus Universitet SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT
US20160220639A1 (en) * 2013-09-11 2016-08-04 New York University Methods and compositions for treating bone diseases
CN104774264B (zh) * 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11259554B2 (en) * 2015-12-16 2022-03-01 Diet4Life Aps Dietary peptides
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11833187B2 (en) 2017-10-23 2023-12-05 The Brigham And Women's Hospital, Inc. Materials and methods for extracellular vessicle-associated diseases
SI3618928T1 (sl) 2018-07-13 2023-04-28 Alector Llc Protitelesa proti sortilinu in postopki za uporabo le-teh
GB202213124D0 (en) * 2022-09-08 2022-10-26 Univ Helsinki Psychiatric disorder

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
WO1993008809A1 (en) * 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US6291247B1 (en) * 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
GB9608335D0 (en) * 1996-04-23 1996-06-26 Univ Kingston Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379
AU7214998A (en) 1997-04-11 1998-11-11 Regents Of The University Of California, The Ngf for the prevention of demyelination in the nervous system
EP0994188B1 (de) 1998-10-09 2004-01-07 Scil proteins GmbH Verfahren zur Gewinnung von aktivem Beta-NGF
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
SE9904863D0 (sv) 1999-12-30 1999-12-30 Medscand Medical Ab New use
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
US7507799B2 (en) 2001-05-25 2009-03-24 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
US7319090B2 (en) * 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
US20060179492A1 (en) * 2002-12-09 2006-08-10 The Regents Of The University Of California Method of inhibiting neural transmission mediated by serotonin-2a and enhancing sensorimotor gating
US8066997B2 (en) * 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
US20060216292A1 (en) * 2003-09-05 2006-09-28 Cellzome Ag Treatment of neurodegenerative diseases
EP1682170A2 (en) * 2003-11-07 2006-07-26 Lay Line Genomics SpA Compositions able to prevent neurodegenerative processes and methods of assaying the same
RS60019B1 (sr) * 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
DK2732823T3 (da) * 2008-06-25 2019-09-16 H Lundbeck As Modulering af TrpV : Vps10p-domæne-receptorsystemet til behandlingen af smerte

Also Published As

Publication number Publication date
ES2777652T3 (es) 2020-08-05
US9234036B2 (en) 2016-01-12
WO2008074329A3 (en) 2008-10-30
LT2120997T (lt) 2017-06-26
PT2120997T (pt) 2017-05-05
US8748384B2 (en) 2014-06-10
US20150023971A1 (en) 2015-01-22
HRP20200416T1 (hr) 2020-06-26
HUE048781T2 (hu) 2020-08-28
WO2008074329A2 (en) 2008-06-26
EP2120997B1 (en) 2017-03-01
PL3225251T3 (pl) 2020-06-29
US20160060346A1 (en) 2016-03-03
HUE031611T2 (en) 2017-07-28
CY1118902T1 (el) 2018-01-10
DK2120997T3 (en) 2017-05-08
HK1245088A1 (zh) 2018-08-24
EP3225251B1 (en) 2020-02-12
LT3225251T (lt) 2020-04-10
HRP20170530T1 (hr) 2017-06-02
US20100210523A1 (en) 2010-08-19
DK3225251T3 (da) 2020-03-16
RS60019B1 (sr) 2020-04-30
EP2120997A2 (en) 2009-11-25
RS55914B1 (sr) 2017-09-29
PL2120997T3 (pl) 2017-08-31
EP3225251A1 (en) 2017-10-04
ES2624180T3 (es) 2017-07-13
PT3225251T (pt) 2020-03-25
SI3225251T1 (sl) 2020-03-31
SI2120997T1 (sl) 2017-08-31

Similar Documents

Publication Publication Date Title
CY1122724T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
AR112564A2 (es) Anticuerpos humanizados contra el receptor del linfoma de burkitt (anti-cxcr5)
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1118377T1 (el) Syk αναστολεις ιμιδαζοπυραζινης
CY1117817T1 (el) Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
CY1113975T1 (el) Παραγοντες για προληψη και θεραπεια διαταραχων που περιλαμβανουν διαφοροποιηση των υποδοχεων ryr
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
ECSP10010230A (es) Derivados de isoxazolo-piridina
MX2009000385A (es) Acil-anilidas sustituidas y metodos de uso de las mismas.
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
MX2009009146A (es) Metodos y objetivos para identificar compuestos para regular la infeccion por rinovirus.
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
UA107929C2 (en) Antibodies against cxcr4 for the treatment of hiv infection
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
CL2008001960A1 (es) Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide.
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
BRPI0418181A (pt) emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson
WO2006065600A3 (en) N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний